In bladder cancers, DRM/Gremlin methylation-positive status was associated with poorer prognosis, while RUNX3 and HPP1 methylation-positive status was associated with poorer disease-free prognosis in prostate cancers. Here, TMEFF2 is linked to prostate carcinoma.